Related Experiment Video
Updated: May 4, 2026

03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
3.3K
Functional cardiac paraganglioma associated with a rare SDHC mutation
Adam C Millar1, Ozgur Mete, Robert J Cusimano
1Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, ON, Canada, amillar@mtsinai.on.ca.
Endocrine Pathology
|January 10, 2014
Summary
This study details a rare functional cardiac paraganglioma in a 41-year-old male. The tumor, associated with an SDHC gene mutation, highlights a novel genetic link for this rare condition.
Area of Science:
- Cardiology
- Oncology
- Genetics
Background:
- Paragangliomas are rare catecholamine-secreting tumors typically found outside the adrenal glands.
- Cardiac paragangliomas, particularly functional ones in the right atrium, are exceptionally uncommon, with limited literature available.
- This case involves a 41-year-old male presenting with a clinically functional cardiac paraganglioma.
Observation:
- A 9.5-cm cardiac mass and a 0.5-cm lung nodule were analyzed.
- Immunohistochemical profiling revealed positivity for chromogranin A and tyrosine hydroxylase, with a global loss of SDHB expression in both tumors.
- The MIB-1 labeling index was <5% in the smaller lesion and bulk of the larger lesion, with foci up to 10% in the larger lesion.
Findings:
- Genetic testing identified an intronic frameshift mutation in the SDHC gene (c.IVS 5+1, G>A).
- This represents the first reported case of a functional cardiac paraganglioma linked to an intronic SDHC gene mutation.
- Both the cardiac mass and lung nodule demonstrated shared immunohistochemical characteristics, suggesting a potential relationship.
Implications:
- This finding expands the known spectrum of genetic mutations associated with paragangliomas.
- Understanding the genetic basis of cardiac paragangliomas is crucial for diagnosis and potential targeted therapies.
- Further research into SDHC mutations and their role in cardiac paraganglioma development is warranted.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy I: Introduction and Classification
826
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790

